Sinopharm Group Co. Ltd.
Other OTCTotal Valuation
Sinopharm Group Co. Ltd. carries a market capitalization of 6.75B, placing it among publicly traded companies globally. Its enterprise value stands at 163.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.75B |
| Enterprise Value | 163.73B |
Share Statistics
Sinopharm Group Co. Ltd. currently has 3.12B shares outstanding.
| Shares Outstanding | 3.12B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Sinopharm Group Co. Ltd. trades at a trailing price-to-earnings ratio of 29.68. The price-to-sales ratio is 0.41, and the price-to-book ratio stands at 1.10.
| PE Ratio | 29.68 |
| PS Ratio | 0.41 |
| PB Ratio | 1.10 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | 45.74 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Sinopharm Group Co. Ltd. trades at an EV/EBITDA multiple of 32.64 and an EV/FCF ratio of 104.13. The EV/Sales ratio of 1.13 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.64 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.13 |
| EV / EBITDA | 32.64 |
| EV / EBIT | 32.64 |
| EV / FCF | 104.13 |
Financial Position
Sinopharm Group Co. Ltd. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 82.54, indicating elevated leverage, while an interest coverage ratio of 13.67 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.35 |
| Quick Ratio | 0.15 |
| Debt / Equity | 82.54 |
| Debt / EBITDA | 20.15 |
| Interest Coverage | 13.67 |
Financial Efficiency
| Return on Equity (ROE) | 470.76 |
| Return on Assets (ROA) | 7.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 4.45 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Sinopharm Group Co. Ltd. has paid 987.09M in income taxes, reflecting an effective tax rate of 23.72.
| Income Tax | 987.09M |
| Effective Tax Rate | 23.72 |
Stock Price Statistics
Sinopharm Group Co. Ltd.'s stock has declined approximately -8.77637% over the past 52 weeks. The 50-day moving average sits at 12.21, while the 200-day moving average is 12.64.
| Beta (5Y) | N/A |
| 52-Week Price Change | -8.77637% |
| 50-Day Moving Average | 12.21 |
| 200-Day Moving Average | 12.64 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sinopharm Group Co. Ltd. generated 144.97B in revenue and converted that into 1.99B in net income, yielding earnings per share of 5.14. EBITDA reached 5.02B, while operating income came in at 5.02B.
| Revenue | 144.97B |
| Gross Profit | N/A |
| Operating Income | 5.02B |
| Pretax Income | 4.16B |
| Net Income | 1.99B |
| EBITDA | 5.02B |
| EBIT | 5.02B |
| Earnings Per Share (EPS) | 5.14 |
Balance Sheet
Sinopharm Group Co. Ltd. holds 43.33B in cash and equivalents against 101.06B in total debt, resulting in a net debt position of 52.28B. Total book value stands at 53.52B, with working capital of 99.12B providing operational flexibility.
| Cash & Cash Equivalents | 43.33B |
| Total Debt | 101.06B |
| Net Debt | 52.28B |
| Equity (Book Value) | 53.52B |
| Book Value Per Share | 86.68 |
| Working Capital | 99.12B |
Cash Flow
After subtracting -1.29B in capital expenditures, free cash flow totaled -1.29B - equivalent to -2.09 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.29B |
| Free Cash Flow | -1.29B |
| FCF Per Share | -2.09 |
Margins
Sinopharm Group Co. Ltd. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 3.46 and net profit margin of 1.37 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | 3.46 |
| Pretax Margin | 2.87 |
| Profit Margin | 1.37 |
| EBITDA Margin | 3.46 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 48.96 |
| FCF Yield | 2.19 |
Scores
Sinopharm Group Co. Ltd. posts an Altman Z-Score of 0.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.95 |